SCHEMBL1574890

SCHEMBL1574890

CCN(c1ccccc1)C1CN(C(=O)Nc2ccccc2Cl)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.51
TSHR P16473 1/20 0.51
TAS1R3 Q7RTX0 2/20 0.50
TAS1R1 Q7RTX1 2/20 0.50
FAAH O00519 2/20 0.50
TAS1R2 Q8TE23 1/20 0.50
P2RX7 Q99572 1/20 0.49
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 4/20 0.43
MAPT P10636 3/20 0.43
EPHX2 P34913 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
KDM4E B2RXH2 3/20 0.42
HPGD P15428 1/20 0.42
POLB P06746 1/20 0.42
KCNQ2 O43526 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575191 0.91 GAA (0.49) GAATSHRTAS1R3TAS1R1FAAH
SCHEMBL1574875 0.87 GAA (0.47) GAAFAAHP2RX7KMT2AEPHX2
SCHEMBL1574665 0.87 TAAR1 (0.50) GAATSHRTAS1R3TAS1R1KMT2A
SCHEMBL1575172 0.86 KDM4E (0.58) GAATAS1R3TAS1R1FAAHKMT2A
SCHEMBL1574839 0.85 GAA (0.55) GAATSHRTAS1R3TAS1R1FAAH
SCHEMBL1574990 0.85 NPSR1 (0.47) GAATSHRKMT2AMEN1ALDH1A1
SCHEMBL1575091 0.84 TAS1R3 (0.53) GAATSHRTAS1R3TAS1R1FAAH
SCHEMBL1574559 0.84 KDM4E (0.56) TSHRKMT2AMEN1ALDH1A1LMNA
SCHEMBL1575133 0.84 HPGD (0.52) TSHRFAAHKMT2AMEN1ALDH1A1
SCHEMBL1574610 0.83 MAPT (0.51) GAATAS1R3TAS1R1FAAHTAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-B1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO (JP) 2015-02-25 EP disclosed
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB GAA 387/4885TSHR 2961/4885TAS1R3 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.